Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Itolizumab [Bmab 600], Bmab600, EQ001
Itolizumab · 3 trials · 7 indications
Number of participants with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Overall Response Rate (ORR) is defined as the number of subjects with a partial response (PR), very good partial response (VGPR), or complete response (CR) who are alive at Day 29. Subjects must not have received new systemic therapy for aGVHD before the Day 29 Visit.
| Arm | Type | Description |
|---|---|---|
| EQ001 Type A cohort | EXPERIMENTAL | EQ001 administered in an unblinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 2 doses (up to 5 cohorts with dosing to be determined in the range of 0.4 -- 3.2 mg/kg). |
| EQ001 for Type B cohort | EXPERIMENTAL | EQ001 administered in an unblinded single dose cohort by subcutaneous injection every two weeks for a total of 13 doses (1.6 mg/kg). |
| EQ001 Dose Escalation (Part A) | EXPERIMENTAL | Open label EQ001 administered by intravenous infusion every two weeks for a total of 5 doses. |
| EQ001 (Part B) | EXPERIMENTAL | EQ001 administered in a blinded fashion using the optimal dose selected from Part A by intravenous infusion every two weeks for a total of 5 doses. |
| EQ001 Placebo (Part B) | PLACEBO_COMPARATOR | Placebo administered in a blinded fashion by intravenous infusion every two weeks for a total of 5 doses. |
| EQ001 | EXPERIMENTAL | EQ001 administered in a blinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 5 doses. |
| EQ001 Placebo | PLACEBO_COMPARATOR | Placebo administered in a blinded dose escalating cohort fashion by subcutaneous injection every two weeks for a total of 5 doses. |
| Name | Type | Description |
|---|---|---|
| Itolizumab [Bmab 600] | DRUG | EQ001 |
| EQ001 | BIOLOGICAL | Itolizumab \[Bmab 600\]) |
| EQ001 Placebo | BIOLOGICAL | EQ001 Placebo |
Type A Cohort Key Inclusion Criteria: 1. Is male or female, age ≥ 18 and ≤ 75 years 2. Has previously been documented to have met or currently meets Systemic Lupus International Collaborating Clinics (SLICC) and/or American College of Rheumatology (ACR) criteria for SLE 3. Received at least 1 immun...
Top 20 of 34 competitors
Itolizumab is an investigational monoclonal antibody developed by Equillium, Inc. (ticker EQ) for lupus erythematosus. It is a CD6 inhibitor and is being studied in immunology. Itolizumab is also known as Bmab 600. It has been evaluated in a Phase 1 clinical trial in systemic lupus erythematosus with or without active proliferative nephritis.
Itolizumab is being developed for lupus erythematosus, including systemic lupus erythematosus with or without active proliferative nephritis. It is an investigational therapy and is not approved for commercial use. Equillium, Inc. (ticker EQ) is the developer. The clinical program has focused on patients 18 years and older.
Itolizumab targets CD6, a cell surface receptor involved in T cell activation. Itolizumab is classified as a CD6 inhibitor. By binding CD6, itolizumab is designed to modulate T cell activity, which is relevant in autoimmune conditions such as lupus erythematosus. It is a monoclonal antibody being developed by Equillium, Inc. (ticker EQ).
Itolizumab is developed by Equillium, Inc., which trades under the ticker EQ. Equillium is advancing itolizumab as an investigational monoclonal antibody for lupus erythematosus. The drug is also known as Bmab 600. Development has included a Phase 1 study in systemic lupus erythematosus with or without active proliferative nephritis.
Itolizumab is in Phase 1 clinical development. The completed Phase 1 trial, NCT04128579, enrolled 52 participants with systemic lupus erythematosus with or without active proliferative nephritis. Itolizumab is investigational and has not been approved by the FDA. Equillium, Inc. (ticker EQ) is the developer. No active trials are currently listed.
Itolizumab has been studied in the Phase 1 trial NCT04128579, titled Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis. The trial enrolled 52 participants across the United States, India, and Poland and is completed. It was a controlled study in adults 18 years and older, and it was not randomized or double blinded.
Yes, itolizumab is also known as Bmab 600. Both names refer to the same monoclonal antibody developed by Equillium, Inc. (ticker EQ). Itolizumab is a CD6 inhibitor being studied in lupus erythematosus. The alternative name Bmab 600 may appear in scientific literature and trial records for the same investigational asset.